AVP and autosomal dominant polycystic kidney disease: The only medication that has been approved for the treatment of ADPKD so far is tolvaptan®, a vasopressin V2 receptor antagonist which targets the antidiuretic hormone arginine vasopressin (AVP)-stimulated cAMP production.